DEF 14A: SI-BONE, Inc. Announces 2024 Annual Meeting of Stockholders, Outlines Key Business Achievements and Governance Proposals

SI-BONE, Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 25, 2024, and the proxy statement details key business achievements, director nominations, and governance proposals.

Summary

• SI-BONE, Inc. will hold its Annual Meeting of Stockholders virtually on June 25, 2024.
• Stockholders will vote on the election of directors, ratification of the independent auditor, an advisory vote on executive compensation, and an amendment to the certificate of incorporation.
• The company achieved worldwide revenue of $138.9 million in 2023, a 31% increase over 2022.
• Over 95,000 iFuse procedures have been performed since inception, with over 1,600 physicians performing the procedure in 2023, a 23% increase over 2022.
• Gross margins for 2023 were 79%, with a 30% improvement in Net Loss and a 48% improvement in Adjusted EBITDA.
• The company exited 2023 with $166 million in cash and equivalents, including $84 million from a follow-on offering in May 2023.
• A new patent was received for a triangular broach instrument, providing protection through 2034 and extended patent protection of our first-generation iFuse to December 2025, with iFuse-3D patent coverage to September 2035.
• The Board of Directors recommends voting in favor of all proposals.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and strategic advancements, indicating a favorable sentiment.

Positives

• Strong revenue growth of 31% year-over-year, reaching $138.9 million in 2023.
• High gross margins of 79% for the full year 2023.
• Significant improvement in Net Loss (30%) and Adjusted EBITDA (48%).
• Solid balance sheet with $166 million in cash and equivalents at the end of 2023.
• Increased adoption of iFuse procedure, with a 23% increase in physicians performing the procedure in 2023.
• Extended patent protection for key technologies, ensuring market exclusivity.
• High say-on-pay approval of 92%.

Negatives

• The company is still reporting a Net Loss and negative Adjusted EBITDA, although improvements have been made.
• Two directors, Helen Loh and Keith C. Valentine, are stepping down at the conclusion of the Annual Meeting, reducing the board size to eight directors.

Risks

• Failure of stockholders to ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm could require the Audit Committee to reconsider its selection.
• Adverse impacts to the company's reputation or financial performance could result from failure to maintain an effective risk management process.
• Cybersecurity incidents could disrupt operations and compromise sensitive information.
• Failure to attract and retain key personnel, including executive officers and directors, could negatively impact the company's performance.

Future Outlook

The company aims to continue introducing new products and training physicians to grow its core business, advancing its mission to help patients.

Management Comments

• Laura Francis, CEO: 'We have made significant and measurable progress since last years annual meeting of stockholders.'
• Laura Francis, CEO: 'I continue to be humbled by the exceptional performance of the entire SI-BONE team, working diligently to introduce new products and continuing to train and educate physicians to grow our core business.'

Industry Context

SI-BONE operates in the medical device industry, specifically focusing on musculoskeletal disorders of the sacropelvic anatomy. The company competes with other medical device companies in the areas of sacroiliac joint dysfunction and pelvic fixation.

Comparison to Industry Standards

• The compensation peer group includes Alphatec Holdings, LeMaitre Vascular, Sight Sciences, Apyx Medical, NeuroPace, Silk Road Medical, AxoGen, OrthoPediatrics, Treace Medical Concepts, Cerus, Pulmonx, ViewRay, ConforMIS, SeaSpine Holdings, Zynex, Cutera, and ShockWave Medical.
• The company's PSU awards are based on total shareholder return relative to a group of industry peers, aligning executive compensation with long-term share price growth and relative outperformance.

Management Changes

Corporate Governance

Related Party Transactions

• The company had a joint development agreement with SeaSpine Orthopedics Corporation (now merged with Orthofix Medical, Inc.), where Keith Valentine, a member of SI-BONE's Board, previously served as President, CEO, and a board member.
• SI-BONE made royalty payments of $0.3 million to SeaSpine for the year ended December 31, 2023, and an immaterial amount for the year ended December 31, 2022, related to the joint development agreement.

Stakeholder Impact

• Shareholders: The company's performance and governance decisions directly impact shareholder value.
• Employees: Compensation and benefits policies affect employee morale and retention.
• Patients: The company's products and services aim to improve patient outcomes.
• Healthcare Professionals: Training and education programs support the adoption of the company's products.

Next Steps

• Stockholders are encouraged to vote their shares as promptly as possible.
• The company will file a Certificate of Amendment to its Certificate of Incorporation if stockholders approve the proposal to limit officer liability.
• The Board and Compensation Committee intend to consider the results of the advisory vote on executive compensation in future decisions.

Key Dates

Keywords

Annual Meeting, Proxy Statement, SI-BONE, iFuse, Board of Directors, Executive Compensation, Revenue, Adjusted EBITDA, Sacroiliac Joint, Medical Device